In papillary thyroid cancer (PTC), BRAF mutation (and hence activation of the MAPK pathway) was associated with decreased radioiodine avidity [24]–[26], which can be explained by BRAF mutation-associated silencing of thyroid iodide-handling genes, such as NIS[18], [27], Tg[27], and TPO[26]–[29]. The gene discussed is BRAF; the disease is thyroid gland papillary carcinoma.